Table 1:

Femoral access-site complications

TNK (n = 46)TPA (n = 93)P Value
Baseline
 Age (IQR)73 (64–79)74 (62–83).62
 Female24 (52.2%)44 (64.7%).59
Risk factors
 Arterial hypertensiona39 (84.8%)64 (69.6%).05
 Type 2 diabetesa11 (23.9%)19 (20.7%).66
 Dyslipidemiaa29 (63.0%)49 (53.3%).27
 Coronary artery diseasea10 (21.7%)22 (23.9%).78
 Atrial fibrillationa13 (28.3%)38 (41.3%).14
 Chronic kidney diseasea8 (17.4%)13 (14.1%).62
 Ischemic strokeb9 (19.6%)22 (23.7%).59
 Smoking (ever)c26 (56.5%)40 (44.0%).16
Primary presentation at CSC26 (56.5%)29 (31.2%).004
LKW to IV thrombolytic (IQR)109 (90–149)119 (91–172).28
IV thrombolytic to groin puncture (IQR)74 (48–109)91 (66–136).07
Antithrombotics23 (50.0%)45 (48.4%).86
 Aspirin18 (39.1%)31 (33.3%)
 Aspirin and Clopidogrel3 (6.5%)5 (5.4%)
 Clopidogrel0 (0.0%)1 (1.1%)
 Coumadin1 (2.2%)4 (4.3%)
 Aspirin and Coumadin0 (0.0%)1 (1.1%)
 Clopidogrel and Coumadin1 (2.2%)3 (3.2%)
Periprocedural
 8F femoral sheath46 (100.0%)93 (100.0%)NA
 Sonographically guided access0 (0.0%)0 (0.0%)NA
 Angio-Seal closure device46 (100.0%)93 (100.0%)NA
Coagulation labs < 12h
 INR (IQR)d1.07 (0.99–1.12)1.18 (1.09–1.31).001
 PT (IQR)e14 (13–15)15 (14–16).001
 aPTT (IQR)f30 (28–31)29 (28–32)1.00

  • Note:—IQR indicates interquartile range; LKW, last known well; aPTT, activated partial thromboplastin times; NA, not available.

  • ↵a Data missing in 1 TPA.

  • ↵b Data missing in 3 TPAs.

  • ↵c Data missing in 5 TPAs.

  • ↵d Data available in 22 and 45 patients with TNK and TPA, respectively.

  • ↵e Data available in 22 and 46 patients with TNK and TPA, respectively.

  • ↵f Data available in 18 and 29 patients with TNK and TPA, respectively.